M MaxCyte® Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT, MXCN February 2022 are trademarks of MaxCyte, Inc. in the U.S.A. ® ® ® ® TM © 2019 MaxCyte, Inc. All Rights Reserved info@maxcyte.com | www.maxcyte.com ir@maxcyte.com | www.maxcyte.com Disclaimer The content of this document (the "Presentation") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"), as amended. Reliance on ...

MaxCyte, Inc. (NASDAQ:MXCT) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Douglas Doerfler - Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Company Evan Stampler - Stifel Matthew Larew - William Blair Vidyun Bais - BTIG Jacob Johnson - Stephens Sean Menarguez Good afternoon, everyone. My name is Sean Menarguez, and I'm an analyst on the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 333-257810 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

MaxCyte, Inc. (NASDAQ:MXCT) Q2 2021 Earnings Conference Call September 13, 2021 4:30 PM ET Company Participants Sean Menarguez - IR Doug Doerfler - CEO Amanda Murphy - CFO Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Co. Dan Arias - Stifel Matt Larew - William Blair Mark Massaro - BTIG Jacob Johnson - Stephens, Inc. Sean Menarguez Good afternoon, everyone. Thank you all for participating in today's conference call. On the call for MaxCyte, we have Doug Doerfler, Chief E ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 333-257810 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...